Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Consensus Statement, the authors present results from an international multi-stakeholder consensus conducted by the PIONEER consortium to identify the most important questions in the field of prostate cancer that could be addressed using big data.
Non-invasive liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) are promising tools for urothelial carcinoma diagnosis and management. In this Review, the authors provide an overview of the different liquid biopsy technologies available, and discuss the current state as well as future perspectives of ctDNA and utDNA application in urothelial carcinoma clinical care.
In this Review, the authors provide an overview of the role of calcium as a driver of prostate cancer onset and progression, and discuss the most current therapies targeting the calcium signalling machinery to treat this malignancy.
In this Review, Nolla and colleagues discuss the use of patient-reported outcome measures (PROMs) to assess health-related quality of life in six immunotherapy versus sunitinib clinical trials for advanced renal cell carcinoma and, following this discussion, make recommendations for future PROM use in clinical trials.
The cellular action of SARS-CoV-2, the virus responsible for the COVID-19 global pandemic, is dependent on a specific combination of receptors and cofactors. These proteins are now known to be expressed in normal kidney tubule tissue and renal cell carcinoma cells, representing possible targets for budding therapeutic modalities.
In this Perspective, current evidence to support de-escalation strategies of attenuated chemotherapy, radiotherapy and surgery for stage II seminoma to minimize the toxic effects of treatment is described and new potential de-escalation strategies are discussed.
In this Review, current vaccine-based approaches to treat prostate cancer are described. The authors discuss results from clinical trials in which overall vaccine safety and biological activity were shown, albeit with modest clinical activity, suggesting that the future of these approaches will be as part of combination therapies with agents targeting tumour-associated immune mechanisms of resistance.
Prostate cancer depends on the hormonal environment for growth. In this Review, the authors describe how this hormonal dependency can be studied in preclinical models. Advantages and limitations of these models are discussed to maximize the transfer of knowledge from scientific research to clinical applications.
Several approaches have been used to date to reproduce human spermatogenesis in vitro, which, however, mostly result in incomplete differentiation. In this Review, the authors describe advantages and limitations of current technologies for in vitro spermatogenesis. New approaches that could lead to the clinical translation of this technology to treat patients with male factor infertility are also discussed.
In this Review, the authors describe the evolution of vaginoplasty including surgical techniques, complications, and clinical and patient-reported outcomes and consider current controversies in techniques and areas for improvement.
Here, the authors explore how environmentally driven changes in the sperm epigenome can mediate paternal contributions to offspring health. They also describe innovations in human stem cell models that can be used to elucidate the paternal origins of health and disease.
Health-related quality of life can be affected by muscle-invasive bladder cancer treatment and should be assessed all the way through patient’s care. In this Review, the authors summarize available data on patient health-related quality of life after curative local treatment for muscle-invasive bladder cancer, also considering the effect of different surgical procedures or urinary diversion methods on patient quality of life.
Since its inception in 1922, prostate biopsy has undergone considerable changes in both technique and indication. In this Perspective, the authors describe the history of prostate biopsy and consider the role of imaging in prostate biopsy, now and in the future.
This Perspective covers existing patient-derived xenografts (PDXs) of prostate cancer, and their features and uses in basic and preclinical research. The authors also discuss the need for additional PDXs, and how collaboration in prostate cancer PDX research can be improved.
In this Review, Lopez et al. discuss the history of penile transplantation, including the procedures and outcomes of transplants to date, as well as factors to consider for consistent, optimal outcomes. The authors also discuss the future of penile transplantation and suggest updates to the Baltimore criteria.
Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk, but optimal screening protocols for individuals with these mutations have been a subject of debate. In this Review, the authors discuss the risk associated with BRCA1/2 mutations and consider how, and whether, a screening programme should be implemented for these individuals.
In this Review, mechanistic findings of growth inhibition by supraphysiological androgens in prostate cancer are described, and insights from the results of using supraphysiological testosterone and the future clinical development of bipolar androgen therapy as an option for prostate cancer are discussed.
New evidence suggests that patients undergoing robotic-assisted radical cystectomy for non-metastatic bladder cancer experience better response in terms of days alive and out of the hospital than patients undergoing open radical cystectomy. The robotic approach was associated with improved post-operative mobilization, decreased transfusion requirement and reduced burden on perceived quality of life.
Combination treatment with androgen deprivation therapy plus chemotherapy or novel hormonal agents showed promising results for the treatment of patients with newly diagnosed metastatic prostate cancer. However, real-world data show a very low uptake of this therapy in clinical practice. In this Perspective, the authors discuss data and potential reasons behind this trend.
This Review summarizes current knowledge regarding salvage high-dose chemotherapy in relapsed germ cell tumours. The authors outline data from phase I and II clinical trials, phase III randomized trials and retrospective datasets, discuss controversies and provide recommendations.
